Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fluarix Tetra + Vaxigrip Tetra + Fluquadri + Fluad Quad + Afluia Quad + Flucelvax Quad-University of Melbourne-influenza-COVID-19
- Development stage
- Unknown
- Lead developer
- University of Melbourne
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
This entry refers to a specific collection of vaccines evaluated in a longitudinal cohort study led by the University of Melbourne (NCT03275311). The study investigates the immunological consequences of repeated annual influenza vaccination and the impact of SARS-CoV-2 infection or vaccination on healthcare workers. The influenza component includes several quadrivalent vaccines: Fluarix Tetra (GSK), Vaxigrip Tetra (Sanofi), Fluquadri (Sanofi), Fluad Quad (adjuvanted, CSL Seqirus), Afluria Quad (CSL Seqirus), and Flucelvax Quad (cell-culture derived, CSL Seqirus). The COVID-19 component involves the administration of Comirnaty (Pfizer/BioNTech) or Vaxzevria (AstraZeneca). These vaccines function by inducing active immunity against specific viral antigens—hemagglutinin for influenza and the spike protein for SARS-CoV-2—to elicit protective antibody and cellular immune responses.
- Brand names
- Afluria QuadFlucelvax QuadComirnatyVaxzevria
- Other names
- Afluria Quad
02
Targets
SARS-CoV-2 spikeHA (Hemagglutinin)
Beyond the preview
Go deeper on Fluarix Tetra + Vaxigrip Tetra + Fluquadri + Fluad Quad + Afluia Quad + Flucelvax Quad-University of Melbourne-influenza-COVID-19.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Fluarix Tetra + Vaxigrip Tetra + Fluquadri + Fluad Quad + Afluia Quad + Flucelvax Quad-University of Melbourne-influenza-COVID-19.